Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the American Society of Microbilogy
https://asm.org/Biographies/Gustavo-Goldman
From the White house link page 19
2. Anti-microbial resistant (AR) pathogens, including bacteria and fungi: CDC’s analysis, COVID-19:
U.S. Impact on Antimicrobial Resistance, Special Report 2022, demonstrated significant surges in
antibiotic use and AR infections during the first year of the pandemic in U.S. hospitals, including a
15% increase in both resistant hospital-onset infections and deaths. Prevention strategies—such as
antibiotic stewardship and infection prevention and control activities—remain the first line of
defense to stop the emergence and spread of AR, while simultaneously helping prepare for
unknown emerging threats in the future. Additionally, improved surveillance and reporting,
accurate and rapid diagnostic tests, and accelerated product development for new vaccines,
therapeutics, antibiotics and antifungals are all critical needs to address AR.
ClinicalTrials.gov updated September 16, 2022 for....
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04784897?term=brilacidin&draw=2&rank=2
No.. It is completely correct.
Directly from the MHSRS website...
Title:Brilacidin, a host defense peptide mimetic, is a broad-spectrum countermeasure strategy against acutely infectious viruses
Accepted Abstract submission for the MHSRS conference in September 2022.
look at the last line of the abstract from Dr Aarthi Narayaan
Brilacidin has also undergone several clinical studies for multiple indications, using different routes of administration, and has a known safety profile in humans.
Abstract ID: MHSRS-22-05925
Submitter Details:
Affiliation:INDUSTRY
Status:Civilian, Other (Non-Government)
Name:Dr. Aarthi Narayanan
Primary Email:aarthin@gmail.com
Secondary Email:aarthin@gmail.com
Phone:(703) 365-2700 ext. 2315
Organization:American Type Culture Collection
Manassas, VA 20110
United States
Presenter Details:
Affiliation:INDUSTRY
Status:Civilian, Other (Non-Government)
Name:Dr. Aarthi Narayanan
Primary Email:aarthin@gmail.com
Secondary Email:aarthin@gmail.com
Phone:(703) 365-2700 ext. 2315
Organization:American Type Culture Collection
Manassas, VA 20110
United States
Co-Authors Detail:
Carol Anderson1, Michael Barrera2, Niloufar Boghdeh2, Kyle Weston3, Jane Harness3, Aarthi Narayanan1
1American Type Culture Collection
2George Mason University
3Innovation Pharmaceuticals
Abstract Details:
Breakout Session:Development of New Front Line Therapies to Prevent & Treat Endemic Viral Diseases (non SARS CoV-2)
Submission Category:Oral Presentation
Title:Brilacidin, a host defense peptide mimetic, is a broad-spectrum countermeasure strategy against acutely infectious viruses
Abstract:
Introduction: Acutely infectious viruses including those that are transmissible by the respiratory and aerosol routes pose critical threats to the warfighter and the civilian population. Aerosol-transmissible pathogens, such as bunyaviruses (Rift Valley fever virus [RVFV]), and alphaviruses (Venezuelan Equine Encephalitis Virus [VEEV], Eastern Equine Encephalitis Virus [EEEV]), have broad range of host tropism, retain high rates of infectivity as aerosols, attain high viral load in the host over short periods of time, cause damage to the blood brain barrier (BBB), impact neurological integrity and are likely to contribute to organ damage due to extreme inflammation. These viruses pose nontrivial challenges to the warfighter because no FDA-approved therapeutics or vaccines are currently available that can be rapidly scaled up, field-deployed and thus potentially mitigate the deleterious consequences of inflammation in addition to decreasing viral load. The long-term neurological sequelae that can ensue from these acute viral infections, especially by the aerosol route, can lead to a life-long health burden for the warfighter. These pathogens are also naturally transmitted by mosquito vectors and are known to cause zoonotic disease in animals in addition to affecting humans on an annual basis in the United States and in other parts of the world. This situation could further drive mutations, leading to infectious spillover events between species. There is an urgent, unmet need for broad-spectrum intervention strategies that can ideally control the disease manifestations in the host and the spread of disease as a prophylactic countermeasure. Our ongoing studies with brilacidin, a host defense peptide (HDP)-based mimetic, have successfully demonstrated that brilacidin is able to interfere with viral integrity and exert an antiviral effect in vitro against candidate alphaviruses and bunyavirus. Furthermore, early indications support the potential of brilacidin to also act in an anti-inflammatory capacity by its impact on inflammatory cytokine expression.
Methods: Appropriate cell lines (Vero cells, U87MG cells, HSAE cells, Huh7, and HepG2 cells) were infected with RVFV (MP-12 strain), VEEV (TC-83 and TrD strains) and SINV +/- brilacidin. Culture supernatants and nucleic acid lysates were quantified for extracellular and intracellular viral load and impact on infectivity by plaque and qRT-PCR assays. Impact of brilacidin on cell viability and lack of toxicity were ascertained by CellTiter Glo assay. Impact of treatment on inflammatory events were quantified by a combination of PCR (gene expression) and ELISA (protein expression). Early studies involving cell biological mechanisms have involved transmission electron microscopy of virus distribution in infected cells +/- brilacidin.
Results: Our studies to query any potential cytotoxicity and quantify CC50 values for brilacidin have indicated that the compound is very well tolerated by a wide breadth of cell lines including those of neuronal origin. The CC50 values for brilacidin in some representative cell types are: Veros: 64.90 µM U87MGs >100 µM, HSAECs: 61.32 µM, Huh7s: 12.03 µM, HepG2s: 153.3 µM. Studies that queried the antiviral activities of brilacidin were also tailored to address mechanism of action and target validation. For candidate alphaviruses and bunyavirus, the following treatment conditions were assessed: pre-treatment only (Pre), pre-treatment + post-treatment (Pre+Post), virus-incubation only (Virus), pre-treatment + virus-incubation + post treatment (Pre + V + Post). For VEEV, our data demonstrated that in both Vero cells and U87MG astrocytes, the Pre + V + Post treatment strategy resulted in >1 log reduction of infectious virus in the culture supernatant. For SINV, an old-world alphavirus, we noticed a higher inhibitory impact on the viral load (> 2 logs) than what was observed in the case of new world alphaviruses. For RVFV, the Pre + V + Post treatment produced the highest antiviral outcome with a decrease in viral load of >2.5 logs. Ongoing studies are focused on obtaining the inhibition profile for EEEV in astrocytes and microglial cells. Our overall assessment of brilacidin targets suggest that brilacidin exerts an impact on the virion integrity directly for several viruses, although the sensitivity to brilacidin differs for different viruses (SARS-CoV-2>RVFV>VEEV). Brilacidin appears to exert its greatest antiviral effect when the virus is directly exposed to brilacidin. Quantification of anti-inflammatory activities in VEEV infection by ELISA demonstrated decrease in IL-1b and IL-6 levels when treated with brilacidin. Early assessments of virus distribution in TC-83-infected cells by electron microscopy is suggestive of potentially lower intracellular viral load upon treatment. Assessment of innate immune activities included quantification of interferon gamma expression by PCR in the context of RVFV infection, which did not indicate a statistically significant change in IFN-ß at the gene expression level. Additional ongoing studies are focused on assessment of brilacidin treatment on a broader array of inflammation-associated genes. Impact of brilacidin on maintenance of BBB integrity in the context of endothelial cells will also be investigated.
Conclusions: The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound. Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution. The observations about anti-inflammatory activities indicate that intracellular events are also modulated by brilacidin treatment that exert a combined protective effect by decreasing viral and inflammatory load. Brilacidin has also undergone several clinical studies for multiple indications, using different routes of administration, and has a known safety profile in humans.
Disclaimer:
Learning Objectives
1. To understand the broad-spectrum potential of brilacidin against aerosol-transmissible acute viruses.
2. To evaluate the mechanism(s) of antiviral activities of brilacidin against enveloped viruses.
3. To ascertain the anti-inflammatory potential of brilacidin in the context of acute virus infections.
Try again....LOL
Fun watching this BS....
Count the shares. They don't match....
LOL
OK...So we now have an additional 10,178 warrant shares on top of the 5,079 preferred shares....15,267 shares * $1080 = $16,488,360 to buy common.
Make the math work for 130M shares...It doesn't.
I'm at $0.126/share now....
It also doesn't match your earlier post on how you got to 130M shares on preferred stock conversions....
Just sayin...
Kips bought Preferred. With the preferred they received warrants for more preferred, which they exercised.
Again-- from the 10Q
Exercise of 2020 Series B-2 5% convertible preferred stock warrants
During the nine months ended March 31, 2022, the Company issued 5,072 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $5.0 million, upon exercise of 3,036 Series 1 warrants and exercise of 2,036 Series 2 warrants issued by the Company. With regard to the exercise of these 5,072 warrants, the Company recorded gross proceeds of approximately $5.0 million to the preferred stock liability.
As of March 31, 2022, there was no Series 1 and 2 warrants outstanding since all warrants were exercised, and there were 1,165 shares of Series B-2 5% convertible preferred stock outstanding.
During the period from December 4, 2020 (date of securities purchase agreement) to June 30, 2021, the Company issued 3,053 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $3.0 million, upon exercise of 3,053 Series 1 warrants issued by the Company. In addition, the Company issued 2,053 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $2.0 million, upon exercise of 2,053 Series 2 warrants issued by the Company. With regard to the exercise of these 5,106 warrants, the Company recorded gross proceeds of approximately $5.0 million to the preferred stock liability.
As of June 30, 2021, there was 5,072 Series 1 and 2 warrants to purchase 5,072 shares of Series B-2 5% convertible preferred stock outstanding and there was no Series B-2 5% convertible preferred stock outstanding
Also from the the 10-Q
On December 4, 2020, the Company entered into a securities purchase agreement (the “Series B-2 Securities Purchase Agreement”) with KIPS Bay Select LP for the sale of an aggregate of 5,089 shares of the Company’s Series B-2 5% convertible preferred stock (the “Series B-2 preferred stock”), for aggregate gross proceeds of approximately $5.0 million. An initial closing for the sale of 3,053 shares of the Series B-2 preferred stock closed on December 9, 2020 for aggregate gross proceeds of approximately $3.0 million, and a second closing for the sale of 2,036 shares of the Series B-2 preferred stock closed on February 8, 2021 for aggregate gross proceeds of approximately $2.0 million.[/quote
From what I find Kips Bay only had 5089 preferred shares that could be converted....At $1080 share (your number) that is roughly $5.5 mil of common stock. I can't get to 130M shares....Unless they all converted at $.042/share. Pretty sure that didn't happen.
Help me find where Kips Bay had more than the 5089 preferred shares....TIA
.
So if Kips Bay had 130M common shares at some point they would have owned around 28% of all common shares outstanding for IPIX. Do you think that they would need to disclose that?
Until then we wait and hope they don’t go 0-6 in P2’s
Thank you. Glad you were able to forward the link.
Had a link to post off of faceb00k....
A real Dr discussing the reality of COVID with a school board making decisions for this upcoming school year.
Somehow someone shut it down...LOL...
Go IPIX!!!! SI 426!!!
With the MHSRS being a very large conference, they chose The Gaylord Palms Resort for the venue. It has up to 76 meeting rooms so multiple presentations be scheduled at the same time. You pick and choose which presentation(s) you want to go to. I don't believe anyone would waste their time on a 5 minute presentation for any topic.
I wonder what
nothing burger
More recently, we evaluated Brilacidin efficacy against other enveloped viruses such as the alphavirus, Venezuelan equine encephalitis virus (VEEV), a category B select pathogen. Early studies suggest robust inhibition of viral load against the VEEV TC-83 strain using Brilacidin in vitro. Ongoing studies are focused on expanding the inhibitory potential of Brilacidin in the context of fully virulent strains of VEEV and Eastern equine encephalitic virus (EEEV).
There are a total of 1673 abstracts listed on the Military Health System Research Symposium (MHSRS) conference website. Of those, 381 were intended for oral presentation including the IPIX presentation ‘Brilacidin, a host defense protein/peptide (HDP) mimetic, is a broad spectrum inhibitor of acutely infectious viruses’. The abstract listed the following learning objectives:
1.Attendee will be able to describe Host Defense Proteins/Peptides (HDPs) and synthetic, non-peptidic small molecule mimetic of HDPs and how they relate to each other.
2.Attendee will able to recognize encephalitic alphaviruses and the threat they pose to warfighter due to their aerosolization capability.
3.Attendee will be able to analyze the effects of Brilacidin on viral replication and its potential use as a therapeutic.
The IPIX presentation was 1 of 4 in the area of ‘Development of New Front Line Therapies to Prevent & Treat non SARSCov-2 Endemic Viral Diseases’.
The remaining 3 abstracts covered topics discussing vaccines for influenza, biomimetic peptide oligomers, and advancement of a needle-free injection device.
Go IPIX!
Covid-19 Deaths This Year Have Already Eclipsed 2020's Toll
Did anyone hear "synergistic value"... B + R
And "expanding to other viruses" --- for further research...
GLTA... Go IPIX!!!
Here are comments from George Mason University's Dr. Narayanan's research. This is her explanation of the research she has done with Brilacidin with Remdesivir.
If Ivermectin was that good they would have figured that out 40 years ago.
Leave it for the cattle herd...
A $33 trade. Somebody must have forgot cash to pay for the coffee and donuts before they went to their cubicle this morning. Go IPIX!!!
There’s a 150 share premarket “trade” showing at .22. Bid is still .265. Who knows. Go IPIX.
Great Find!
It is exciting to hear positive comments from Dr. Aarthi Narayanan discussing her research with Brilacidin in the youtube video you posted.
Finally, some solid information from an unbiased researcher- and a real Dr.
GO IPIX!
I've still got a $100 saying you don't get paid...
From your link...Feel free to take a 100X dose.
Ivermectin is not approved by the FDA for the treatment of any viral infection.
Recommendation
There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.
Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell cultures.13 However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.14,1
I get it- they do not want any patient who becomes that ill to be lost to the trial. Hopefully, they would be in the placebo group
WOW! A number of companies work with Russia to do clinical trials...
The list of companies with the highest number of trial approvals in 2018 is topped by Novartis and Roche (Switzerland). Pfizer (USA) made a leap from 15th place to 3rd/4th, sharing it with Janssen Pharmaceutica (Belgium). Next on the list are AbbVie Inc. (USA), AstraZeneca (UK), and Merck & Co. (USA).
U.S. sponsors took the lead among the non-Russian companies, having secured approval for 108 trials in Russia in 2018.
Hey Dud... I marked this post like you told me to....
what trial - the trial that will never start? Leo hasn't started a trial in over 2 years. all he does is raise funds and makes them disappear - never going to trials.
this will be no different - mark this post
Yes... complete sarcasm!
GO IPIX!!!!
Welcome back!
Wall just fell to .465...LOL.
Appreciate your consistency!
Article written last July and posted by...
Trial Expert
You mean their shorts....
You cannot keep repeating the same thing if you get it wrong again and again and again.
Not sure I'd get too rattled about this one...
Here is an excerpt...
There are limitations to our study. This is an open-labelled study, which was stopped early due to the impact of the national pandemic control measures and national prioritisation rules for clinical research trials in the UK. Our power calculations were made from the best available predictions in early 2020. Therapeutic randomised clinical trial design and sample size calculations are often dictated by statistical assumptions with treatment effect estimations based on the evidence of best available care. However, in trial design for a new disease, with no known effective treatment, statistical assumptions are thus arbitrary.
5 million traded...Wow!
Nice volume so far - over 2 million traded today...
Can't say it any better....
Great post!!!!
Go IPIX!!!!
Interesting that we are the only Host defense protein (HDP) mimetic on the list with a different MOA than the others listed.